News Releases

26 Jul '21
New GAIN Trial baseline data demonstrates majority of patients have elevated   Von Willebrand factor and alpha-2-macroglobulin Cortexyme to host AAIC symposium titled “Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Disease Modification” on Tuesday, July 27
22 Jul '21
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 22, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases , announced that it
19 Jul '21
“Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Disease Modification” SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 19, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected in the
26 May '21
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 26, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with topline data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Chris
Displaying 1 - 10 of 16